In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
<iframe src="https://hindustansphere.com/embed/cluster/f57f283cd5993905a34d28744934cea4392ec62d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="DRL says cap on trade margins a positive, posts 36% dip in Q2 PAT"></iframe>
